Autonomix Medical

Autonomix Medical Autonomix (Nasdaq: AMIX) is focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated.

09/01/2026

Autonomix's abstracts for poster presentation at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress highlight the potential of Autonomix’s transvascular technology across pain management and nervous system mapping. For presentation details, visit: https://bit.ly/4xwg6VD

09/01/2026

Autonomix today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. Read more: https://bit.ly/4xwg6VD

08/26/2026

Autonomix's new patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain. Read more: https://bit.ly/4gCZGDH

08/26/2026

“The issuance of this U.S. patent further strengthens our intellectual property position around precisely controlled, feedback-guided intervention of targeted tissue and neural structures,” said Brad Hauser, Autonomix CEO. Read more about our new patent: https://bit.ly/4gCZGDH

08/26/2026

Autonomix today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office (USPTO), titled “Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development” on August 25, 2026. Read more: https://bit.ly/4gCZGDH

08/12/2026

"The successful completion of this GLP pre-clinical study represents a critical step in our regulatory and clinical development strategy," said Brad Hauser, Chief Executive Officer of Autonomix. Read more about the Good Laboratory Practice pre-clinical study: https://bit.ly/4x6ODti

08/12/2026

Autonomix today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). Read more: https://bit.ly/4x6ODti

08/10/2026

"Rob's career has been defined by a relentless pursuit of innovation that has improved the lives of countless patients around the world," said Brad Hauser, President and Chief Executive Officer of Autonomix. Read more about his recognition: https://bit.ly/4q7esH7

08/10/2026

Autonomix congratulates Chief Medical Officer Robert Schwartz, M.S., M.D., FACC, on receiving the 2026 Cardiovascular Tech Forum Lifetime Achievement Award, honoring one of the medical technology industry's most influential innovators whose career has helped shape modern cardiovascular care. Read more: https://bit.ly/4q7esH7

08/04/2026

“This patent represents another meaningful expansion of our intellectual property portfolio and further demonstrates the breadth of our proprietary technology platform,” said Brad Hauser, Chief Executive Officer of Autonomix Medical. Read more about the new patent: https://bit.ly/4buNXFx

Address

The Woodlands, TX
77380

Website

Alerts

Be the first to know and let us send you an email when Autonomix Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category